A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis
This study is conducted to evaluate the pharmacokinetics and safety of INCB161734 in participants with impaired renal function and participants on hemodialysis.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Incyte Corporation Call Center (US)
- 電話番号:1.855.463.3463
- メール:medinfo@incyte.com
研究連絡先のバックアップ
- 名前:Incyte Corporation Call Center (ex-US)
- 電話番号:+800 00027423
- メール:eumedinfo@incyte.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Ability to comprehend and willingness to sign a written ICF for the study.
-
Aged 18 to 85 years, inclusive, at the time of signing the ICF.
-
Severe renal impairment or ESRD based on CKD-EPI (National Kidney Foundation).
• Participants with impaired renal function should have stable renal function (ie, those with acute changes in renal function should not be enrolled in the study).
-
Medical findings consistent with the degree of renal dysfunction, determined by medical history, physical examination, vital sign measurements, 12-lead ECGs, and clinical laboratory determinations at screening or check-in (as applicable). Participants with abnormal findings considered not clinically significant by the medical monitor or investigator are eligible.
-
BMI of 18.0 to 43.0 kg/m2 (inclusive) at screening.
-
Ability to swallow and retain oral tablets.
-
Willingness to avoid pregnancy, breastfeeding, or fathering children.
Exclusion Criteria:
-
History of uncontrolled or unstable cardiovascular, respiratory, renal, GI, endocrine, hematopoietic, psychiatric, or neurological disease within 6 months before screening.
- History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study, including but not limited to the following:
- Recent myocardial infarction (within 6 months before check-in).
- New York Heart Association Class III or IV congestive heart failure.
- Unstable angina (within 6 months before check-in).
- Clinically significant (symptomatic) cardiac arrhythmias (eg, sustained ventricular tachycardia, second or third degree atrioventricular block without a pacemaker).
- Uncontrolled hypertension.
-
Participants who have a current, functioning organ transplant or are on the national transplant list and expected to receive a transplant within 3 months.
-
History of an autoimmune disease diagnosis (eg, myasthenia gravis).
-
History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg at screening, confirmed by repeat testing).
-
Participants who have a 12-lead ECG abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis.
-
Presence or history of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn disease or chronic pancreatitis).
-
History of malignancy within 5 years before screening, with the exception of cured basal cell or squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.
-
Current or recent (within 3 months before screening) clinically significant GI disease or surgery (including cholecystectomy [< 2 months]; excluding appendectomy and hernia repair) that could affect the absorption of study drug.
-
Confirmed resting pulse rate (up to 2 consecutive measurements) < 40 bpm or > 100 bpm at screening.
-
Participants with laboratory values outside the accepted range for participants with severe renal impairment or ESRD at screening.
-
Any major surgery within 4 weeks before screening. Note: This does not include procedure for HD.
-
Blood transfusion within 4 weeks before check-in (Day -1).
-
Chronic or current active infectious disease (including latent tuberculosis) requiring systemic antibiotic, antifungal, or antiviral treatment.
-
Positive test result for HBV, HCV, or HIV. Upon testing, HBV DNA and HCV RNA must be undetectable.
- Note 1: Participants with no prior history of HBV infection who have been vaccinated against HBV and who have a positive HBsAg antibody test as the only evidence of prior exposure may participate in the study.
- Note 2: Participants who have cleared a prior HBV infection (defined as HbsAg negative, HBsAb positive, or HBcAb positive) may be included at the discretion of the investigator.
-
Receipt of any vaccine including but not limited to live (including attenuated), influenza, and SARS-CoV-2 vaccines within 3 months before the first dose of study drug.
-
Medical or self-reported history of alcoholism within 3 years before screening.
-
History of significant alcohol use, defined as regular alcohol consumption > 21 units per week for males and > 14 units for females, within 3 months before screening.
-
Treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with another investigational medication or current enrollment in another investigational drug study.
-
Treatment within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug with an inducer or inhibitor of CYP3A4, P-gp, or BCRP (refer to the Drug Interaction Database Program for prohibited drugs).
-
Active infection requiring systemic therapy.
-
History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
-
Known hypersensitivity or severe reaction to INCB161734, any excipients of INCB161734, or any KRAS inhibitors (refer to the IB).
-
Inability to undergo venipuncture or tolerate venous access, or inadequate veins for repeat venipuncture or venous access as determined by the investigator.
-
Tobacco or nicotine-containing product use of > 10 cigarettes per day within 1 month before screening.
-
Use of prescription drugs (including hormonal contraceptives) within 14 days before study drug administration or nonprescription medications/products (including megadose vitamins, minerals, and phytotherapeutic, herbal, or plant-derived preparations as well as pre/probiotics) within 7 days of study drug administration
- Note 1: Occasional acetaminophen, standard-dose ibuprofen, and standard-dose vitamins are permitted.
- Note 2: Established therapy for renal disease, or the treatment of associated disorders, that has been stable for at least 7 days prior to study drug administration, is allowed if approved by the medical monitor and investigator.
-
Participants who are pregnant or lactating.
-
Excessive exercise (eg, Ironman, bi/triathlon) within 3 months before screening.
-
Participants who had a change in disease status within 30 days before screening, as documented by the participant's medical history, that is deemed clinically significant by the investigator.
-
Participants who have a history of paracentesis within 3 months prior to check-in.
-
Participants who required new medication or an increase in dose for renal disease within 3 months prior to check-in.
-
Participants who have a history of unstable diabetes mellitus (as evidenced by hemoglobin A1c ≥ 10.0%). Medications for treatment of diabetes mellitus must be reviewed and approved by the investigator and medical monitor.
-
Esophageal banding within 3 months prior to check-in or required any other treatment for GI bleeding within 6 months prior to check-in.
Other protocol-defined Inclusion/Exclusion Criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Group 1: Severe renal impairment
Participants with severe renal impairment will be enrolled in Group 1. |
single dose administered orally |
|
実験的:Group 2: End-stage renal disease (ESRD)
Participants with end-stage renal disease will be enrolled in Group 2. |
single dose administered orally |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PK for plasma INCB161734: Cmax
時間枠:Up to approximately 3.5 months
|
Defined as the maximum plasma concentration. |
Up to approximately 3.5 months
|
|
PK for plasma INCB161734: AUClast
時間枠:Up to approximately 3.5 months
|
Defined as the area under the concentration-time curve from time zero to time of the last quantifiable concentration. |
Up to approximately 3.5 months
|
|
PK for plasma INCB161734: AUCinf
時間枠:Up to approximately 3.5 months
|
Defined as the area under concentration-time curve from time zero extrapolated to infinity. |
Up to approximately 3.5 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Treatment-Emergent Adverse Events (TEAEs)
時間枠:Up to approximately 3.5 months and 30 days
|
Adverse events reported for the first time or worsening of a pre-existing event, occurring after first dose of study drug. |
Up to approximately 3.5 months and 30 days
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Incyte Medical Monitor、Incyte Corporation
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- INCB161734-106
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。